A Detailed Analysis of the Myasthenia Gravis Treatment Market Based on Advancements in Immunotherapies, Expanding Research Initiatives, and Increasing Awareness, Fostering the Development of Innovative Therapeutic Interventions
Industry: Healthcare
Published Date: January-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 230
Report ID: PMRREP33757
1. Executive Summary
1.1. Global Myasthenia Gravis Treatment Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Drug Class Lifecycle Analysis
2.4. Myasthenia Gravis Treatment Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Myasthenia Gravis Treatment Market Outlook: Drug Class
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug Class, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
3.3.3.1. Cholinesterase Inhibitors
3.3.3.2. Corticosteroids
3.3.3.3. Immunosuppressants
3.3.3.4. IVIg
3.3.3.5. Monoclonal
3.4. Market Attractiveness Analysis: Drug Class
3.5. Global Myasthenia Gravis Treatment Market Outlook: Distribution Channel
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
3.5.3.1. Hospital Pharmacies
3.5.3.2. Retail Pharmacies
3.5.3.3. Online Pharmacies
3.6. Market Attractiveness Analysis: Distribution Channel
4. Global Myasthenia Gravis Treatment Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia & Pacific
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Drug Class
5.3.3. By Distribution Channel
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
5.5.1. Cholinesterase Inhibitors
5.5.2. Corticosteroids
5.5.3. Immunosuppressants
5.5.4. IVIg
5.5.5. Monoclonal
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
5.6.1. Hospital Pharmacies
5.6.2. Retail Pharmacies
5.6.3. Online Pharmacies
5.7. Market Attractiveness Analysis
6. Europe Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Drug Class
6.3.3. By Distribution Channel
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Turkey
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
6.5.1. Cholinesterase Inhibitors
6.5.2. Corticosteroids
6.5.3. Immunosuppressants
6.5.4. IVIg
6.5.5. Monoclonal
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
6.6.1. Hospital Pharmacies
6.6.2. Retail Pharmacies
6.6.3. Online Pharmacies
6.7. Market Attractiveness Analysis
7. East Asia Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Drug Class
7.3.3. By Distribution Channel
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
7.5.1. Cholinesterase Inhibitors
7.5.2. Corticosteroids
7.5.3. Immunosuppressants
7.5.4. IVIg
7.5.5. Monoclonal
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
7.6.1. Hospital Pharmacies
7.6.2. Retail Pharmacies
7.6.3. Online Pharmacies
7.7. Market Attractiveness Analysis
8. South Asia & Oceania Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
8.5.1. Cholinesterase Inhibitors
8.5.2. Corticosteroids
8.5.3. Immunosuppressants
8.5.4. IVIg
8.5.5. Monoclonal
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
8.6.1. Hospital Pharmacies
8.6.2. Retail Pharmacies
8.6.3. Online Pharmacies
8.7. Market Attractiveness Analysis
9. Latin America Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
9.5.1. Cholinesterase Inhibitors
9.5.2. Corticosteroids
9.5.3. Immunosuppressants
9.5.4. IVIg
9.5.5. Monoclonal
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
9.6.1. Hospital Pharmacies
9.6.2. Retail Pharmacies
9.6.3. Online Pharmacies
9.7. Market Attractiveness Analysis
10. Middle East & Africa Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
10.5.1. Cholinesterase Inhibitors
10.5.2. Corticosteroids
10.5.3. Immunosuppressants
10.5.4. IVIg
10.5.5. Monoclonal
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
10.6.1. Hospital Pharmacies
10.6.2. Retail Pharmacies
10.6.3. Online Pharmacies
10.7. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Corticosteroids
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Alexion Pharmaceutical Inc.
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Grifols SA
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Avadel Pharmaceuticals plc.
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Novartis AG
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Pfizer; Inc.
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. AbbVie Inc.
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. F. Hoffmann-La Roche Ltd.
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. GlaxoSmithKline plc
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Bausch Health Companies Inc.
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Shire plc.
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
